Here’s a list of key deals reported across sectors this week:
Skyworks Solutions (SWKS), which supplies radio frequency chips to Apple (AAPL) and other smartphone makers, has agreed to buy Qorvo (NASDAQ:QRVO) in a cash-and-stock transaction that values the combined enterprise at around $22 billion.
Huntington Bancshares (HBAN) agreed to acquire Cadence Bank (NYSE:CADE) in an all-stock deal valued at ~$7.4B, adding to its presence in the South, particularly in Texas and Mississippi.
Brighthouse Financial (BHF) jumped 20% after a report that Aquarian Holdings was in advanced talks to acquire the US life insurer.
Intel (INTC) is in early discussions to purchase artificial intelligence chip startup SambaNova Systems Inc.
Chewy (CHWY) has agreed to acquire equine health products provider, SmartPak Equine from Covectrus for an undisclosed amount.
PharmaDrug (OTC:PHRX) (OTCPK:LMLLF) has executed a definitive securities exchange agreement to acquire up to a 40% equity interest in Canurta, the company said on Thursday.
Thermo Fisher Scientific (TMO) has confirmed a deal to acquire clinical trial data management firm Clario Holdings from a shareholder group led by Astorg and Nordic Capital, Novo Holding, and Cinven for $8.875 billion in cash at close.
Japan’s NEC Corporation said Wednesday it’s buying CSG Systems International (CSGS), a U.S. supplier of customer care and billing services for cable and phone companies, for $80.70 per share in cash, for a total enterprise value of approximately $2.9 billion, including debt.
Kiwetinohk Energy (OTCPK:KWTEF) said Tuesday that privately-held Cygnet Energy agreed to acquire the company in an all-cash deal valued at C$1.4 billion (~US$998 million) including debt.
Sotherly Hotels (NASDAQ:SOHO) has agreed to be acquired by a joint venture led by Kemmons Wilson Hospitality Partners and Ascendant Capital Partners for $2.25 per share in cash, the companies said on Monday, sparking a rally in premarket activity.
Novartis (NYSE:NVS) (OTCPK:NVSEF) (TSX:NVS:CA) said Sunday it will acquire California-based Avidity Biosciences (NASDAQ:RNA) in a $12 billion all-cash transaction, strengthening the Swiss pharmaceutical company’s portfolio of treatments for rare muscle disorders.